|
||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||
| |
![]() |
|
||||||||||||||||||||||||||||||||||||||||
|
NOTE 2. ACCOUNTING
CHANGES The following is a summary of the impairment charge
by business segment,
This assessment must be conducted at least annually at the reporting unit level, and any such impairment must be recorded as a charge to operating earnings. The annual impairment tests for 2002 and 2003 were performed and no additional impairments were indicated. 2001
Derivatives Effective January 1, 2001, Praxair adopted
SFAS 133, Accounting for Derivative Instruments and Hedging Activities,
as amended by SFAS 137 and 138. SFAS 133 requires all derivatives to be
recorded on the balance sheet at fair value. At January 1, 2001, Praxair
recorded a one-time after-tax charge as a cumulative effect adjustment
for the initial adoption of SFAS 133 totaling $2 million in its consolidated
statement of operations, and a deferred loss of $4 million in the accumulated
other comprehensive income (loss) component of shareholders equity
in the condensed consolidated balance sheet (see Notes
1, 14 and15).
|
||||||||||||||||||||||||||||||||||||||||||
| |
||||||||||||||||||||||||||||||||||||||||||